5α-reductase inhibitors: What role should they play?

Urology

Volumn 58, Issue 6 SUPPL. 1, 2001, Pages 65-70

  Kaplan, Steven A ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b 161 Fort Washington Avenue ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; DOXAZOSIN; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; PRAZOSIN; TERAZOSINE;

CANCER DIAGNOSIS; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HORMONE BLOOD LEVEL; HUMAN; LONG TERM CARE; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SYMPTOM; URETHRA; URINE FLOW RATE; URINE RETENTION; URODYNAMICS; AGED; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PRAZOSIN; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0035653857     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01347-4     Document Type: Conference Paper

References (45)

1. An overview of current concepts in the study of benign prostatic hyperplasia
2. Benign prostatic hyperplasia
3. The pathogenesis of benign prostatic hyperplasia
4. Tissue content of dihydrotestosterone in human prostatic hyperplasia is not supranormal
5. Sex steroid receptors in normal and hyperplastic prostate
6. Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissue; characterization of nuclear salt-resistant receptors
7. Prostatic epidermal growth factor receptors and their regulation by androgens
8. Identification of a cellular receptor for transforming growth factor-8 in rat ventral prostate and its negative regulation by androgens
9. Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase
10. Molecular genetics of steroid 5 alpha-reductase 2 deficiency
11. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression
12. Cell type specific expression of steroid 5 alpha reductase 2
13. Expression and regulation of steroid 5 alpha reductase 2 in prostate disease
14. Familial incomplete male pseudohermaphroditism, Type 2; decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias
15. Steroid 5 alpha-reductase deficiency in man; an inherited form of male pseudohermaphroditism
16. 4-Azasteroid-fra-reductase inhibitors without affinity for the androgen receptor
17. Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors
18. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men
19. Hormonal effects of an orally active 4-azasteroid inhibitor or 5 alpha-reductase in humans
20. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia
21. Androgen metabolism in men receiving finasteride before prostatectomy
22. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia
23. The effect of finasteride in men with benign prostatic hyperplasia
24. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia
25. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia
26. Finasteride in the treatment of benign prostatic hyperplasia; a urodynamic evaluation
27. Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia
28. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia; a pilot study
29. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia; Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group
30. Treatment of benign prostatic hyperplasia
31. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride; meta-analysis of randomized clinical trials
32. Can finasteride reverse the progress of BPH? A two year placebo controlled study
33. Efficacy, tolerability and effect on health-related quality of life of finasteride compared to placebo in men with symptomatic benign prostatic hyperplasia; the community-based urology study of PROSCAR
34. Inhibition of steroid 5 alpha-reductase with finasteride; sleep-related erections, potency, and libido in healthy men
35. Treatment of benign prostatic hyperplasia with 5 alpha-reductase inhibitors
36. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer; effects of finasteride: Finasteride PSA Study Group
37. Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with finasteride
38. The effects of finasteride on serum prostate specific antigen (PSA) in men with benign prostatic hyperplasia
39. Treatment with finasteride following radical prostatectomy for prostate cancer
40. The effects of finasteride on serum prostate specific antigen in men with benign prostatic hyperplasia and prostate cancer
41. Chemoprevention of prostate cancer
42. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex
43. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
44. Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia
45. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer; results of a randomized, double-blind, placebo-controlled clinical trial: PLESS Study Group, Proscar Long-Term Efficacy and Safety Study